1. Generic substitution in the treatment of epilepsy: patient and physician perceptions;Berg;Epilepsy Behav,2008
2. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures;Berg;Neurology,2008
3. European Medicines Agency. EMA guideline on the investigation of bioequivalence [En ligne ; disponible sur : https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf (consulté le 26/09/2022)].
4. European Medicines Agency. EMA: Questions and answers on bioequivalence studies [En ligne ; disponible sur : https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-pharmacology-pharmacokinetics/clinical-pharmacology-pharmacokinetics-questions-answers (consulté le 26/09/2022)].
5. Food and Drug Administration. FDA Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations [En ligne ; disponible sur : https://www.fda.gov/files/drugs/published/Bioavailability-and-Bioequivalence-Studies-Submitted-in-NDAs-or-INDs-%E2 %80 %94-General-Considerations.pdf (consulté le 26/09/2022)].